Immunovant (4YB) Cash flow

0 Followers

Immunovant Cash Flow

DE:4YB's free cash flow for Q1 2027 was $-124.41M. For the 2027 fiscal year, DE:4YB's free cash flow was decreased by $-30.68M and operating cash flow was $-124.41M. See a summary of the company’s cash flow.

Cash Flow	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
Operating Cash Flow	$ -407.31M	$ -375.87M	$ -214.23M	$ -188.19M	$ -106.11M
Investing Cash Flow	$ -8.00K	$ -759.00K	$ -360.00K	$ -197.00K	$ -254.00K
Financing Cash Flow	$ 595.76M	$ 454.49M	$ 472.43M	$ 70.89M	$ 200.13M
End Cash Position	$ 902.11M	$ 713.97M	$ 635.37M	$ 376.53M	$ 493.82M
Free Cash Flow	$ -407.32M	$ -376.63M	$ -214.59M	$ -188.39M	$ -106.37M

Currency in USD